NCT07075029 (RAISE) is a clinical trial of NP swabs in Acute Respiratory Infections (ARIs), sponsored by Huashan Hospital.

Who is sponsoring NCT07075029?

NCT07075029 is sponsored by Huashan Hospital.

What drugs are being tested in NCT07075029?

Interventions in NCT07075029: NP swabs.

What condition does NCT07075029 study?

NCT07075029 studies Acute Respiratory Infections (ARIs).

Is NCT07075029 still recruiting?

NCT07075029 is currently not yet recruiting. Last updated 20 July 2025.

Last reviewed 2025-07-20 · How we verify

NCT07075029: RAISE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China

Not yet recruiting Last updated 20 July 2025

What this trial tests

trial testing NP swabs in Acute Respiratory Infections (ARIs) in 28,800 participants. Not yet recruiting.

Timeline

1 September 2025

Primary endpoint
30 November 2027

31 December 2027

Quick facts

Lead sponsor	Huashan Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	28,800
Start date	1 September 2025
Primary completion	30 November 2027
Estimated completion	31 December 2027
Sites	13 locations across China

Drugs / interventions tested

NP swabs

Conditions studied

Acute Respiratory Infections (ARIs) — all drugs for Acute Respiratory Infections (ARIs) →

Sponsor

Huashan Hospital

Who can join

Eligibility, any sex, with Acute Respiratory Infections (ARIs). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, observational, community-based study designed to evaluate the incidence of respiratory syncytial virus (RSV) infection among community-dwelling elderly individuals in China, as well as their cohabiting older adults and children, over a 24-month period. During the study, home visits will be conducted to collect nasopharyngeal (NP) swabs from all community residents aged ≥50 years who report symptoms of acute respiratory infection (ARI). Pathogen detection will be performed using both point-of-care testing (POCT) and centralized laboratory analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Infections (ARIs)

Currently open trials in the same condition.

NCT07211997 — FebriDx® Pediatric Validation Study · recruiting

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT06923280 — Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07075029 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 20 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07075029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing